Xatral XL

Quick links

Choose a section

Quick links to important sections

Advertisements

Xatral XL

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Xatral XL

What is Xatral XL? A Definitive Overview

Property Description
Active ingredient Alfuzosin hydrochloride
Form Prolonged-release tablet (XL formulation)
Pharmacological class Selective Alpha-1-Adrenoceptor Antagonist (Alpha-Blocker)
General purpose To ease resistance to urine flow
Origin Synthetic compound (Quinazoline derivative)

Definition and Core Composition

Xatral XL is an oral, prescription-only medication containing the active ingredient Alfuzosin hydrochloride. It is a synthetic compound used in monotherapy, derived from the quinazoline chemical structure. This medicine is classified as an alpha1-blocker, a specialized form of alpha-adrenoceptor antagonist. The product's key differentiator is its XL (eXtended-Length) formulation—a prolonged-release tablet designed to provide a steady effect over 24 hours.


Understanding the Selective Alpha-Blocker Classification

Being an alpha1-blocker, the drug works by blocking specific nerve signals that cause muscle tissues to contract, thus achieving smooth muscle relaxation. Alfuzosin is described as a uroselective compound because its action is predominantly targeted at the alpha1-adrenoceptors in the lower urinary system, specifically the prostate and the bladder neck. This selective mechanism is essential for conditions where muscular tone obstructs the natural flow pathway.


What Does the XL Formulation Mean for its Purpose?

This sustained-release delivery mechanism is designed to maintain a stable, consistent level of Alfuzosin hydrochloride throughout the entire dosing period, contrasting with standard immediate-release forms. The prolonged-release design supports the general therapeutic purpose: to provide continuous smooth muscle relaxation and thereby reduce resistance to urine flow in the lower urinary tract.

Regulatory References

  1. MedlinePlus Alfuzosin Drug Information
Advertisements

What side effects are possible with Xatral XL?

Possible Side Effects and Safety Information

The safety profile of Xatral XL (alfuzosin hydrochloride) is structured according to standardized regulatory documentation, classifying potential adverse reactions by frequency and affected body system. The most commonly documented adverse reactions, classified as Common, include dizziness, headache, nausea, abdominal pain, and general malaise or fatigue. Reactions related to the vascular system, such as postural hypotension (dizziness upon standing), are also common, particularly at the beginning of treatment or following re-initiation.


Frequency and Organ Systems

Uncommon documented effects include syncope (fainting), tachycardia (increased heart rate), diarrhea, rhinitis, and skin reactions like rash or pruritus. These effects are grouped into system-organ classes such as Nervous System Disorders, Gastrointestinal Disorders, Cardiac Disorders, and Vascular Disorders in official labeling.


Serious Adverse Reactions and Constraints

Serious adverse reactions, though typically rare or reported post-marketing, are explicitly documented in regulatory texts. These include priapism (a persistent, painful erection), severe low blood pressure leading to syncope, and reports of hepatocellular injury or cholestatic liver disease. A surgical safety consideration known as Intraoperative Floppy Iris Syndrome (IFIS) has also been documented in patients using alpha-1 blockers.

Important safety constraints established by regulatory authorities include that Xatral XL is contraindicated in patients with severe hepatic impairment. Additionally, special caution is advised for patients with pre-existing Coronary Artery Disease, as the product has been associated with a very rare risk of angina pectoris aggravation.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation identifies the primary manifestation of Xatral XL (Alfuzosin hydrochloride) overdosage as severe hypotension, a pronounced drop in blood pressure. This effect is a documented consequence of the drug’s pharmacological class. Potential severe outcomes are generally associated with prolonged and persistent low blood pressure, which may include syncope.

Regulators emphasize that for any suspected overdosage, immediate medical attention is required. Contacting emergency services immediately is mandated if the affected individual has collapsed, has trouble breathing, or cannot be awakened. The official procedure requires the victim to be immediately hospitalized for urgent care and continuous observation.

Official Management and Monitoring

Management focuses strictly on supportive measures, as no specific antidote is known for Alfuzosin overdosage. Supportive measures listed in regulatory information include placing the patient in the supine position and initiating support of the cardiovascular system as a first priority. Conventional treatment for hypotension involves administering intravenous fluids. Vasopressors may be used if the severe hypotension persists despite initial fluid therapy. Monitoring and support of renal function are also required. Official labeling notes that hemodialysis is unlikely to be beneficial due to the high protein binding of the active substance.

Advertisements

Therapeutic Uses of Xatral XL

What Xatral XL Treats: Main Uses and Benefits

Xatral XL (alfuzosin) is used for the symptomatic management of the signs and symptoms of benign prostatic hyperplasia (BPH). It assists with easing discomfort and supports general well-being by addressing specific physical manifestations associated with the condition.


Managing Disruptive Urinary Symptoms

This involves lower urinary tract symptoms (LUTS) that create noticeable physiological strain. These symptoms may include:

  • Frequent or urgent urination
  • Difficulty starting the urinary stream
  • A weak or interrupted flow
  • The sensation of incomplete bladder emptying

Xatral XL is relevant for easing symptomatic discomfort, assists with maintaining functional stability, and supports improved day-to-day comfort during symptomatic periods.


Support for Symptomatic Periods

This medication is utilized when symptomatic assistance is needed during phases when BPH symptoms may intensify or become temporarily overwhelming. It is relevant in contexts involving heightened systemic burden and may assist with supportive relief during episodes of increased discomfort.


Supporting Stability and Comfort

Xatral XL helps address symptom clusters that interfere with daily functioning, particularly in conditions involving episodic or fluctuating manifestations. It provides support that helps ease the overall burden of symptoms and assists with maintaining a sense of stability when symptoms are more noticeable, which supports general well-being.

“Used in situations involving certain distressing symptoms.”

Quick Fact: Relief for Noticeable Physiological Strain

Regulatory References

  1. NIH DailyMed Prescribing Information
Advertisements

Eligibility and Restrictions for Use

Xatral XL is officially indicated for use in adult men to manage symptoms of benign prostatic hyperplasia (BPH) or acute urinary retention (AUR). The eligibility profile is strictly defined by regulatory authorities based on pre-existing conditions and concurrent treatments.


Contraindicated Populations

The medicine must not be administered to specific patient groups, constituting an absolute exclusion from use:

  • Patients with moderate or severe hepatic impairment (liver failure) as defined by Child-Pugh categories B and C.
  • Individuals with a known history of orthostatic hypotension (postural hypotension) or hypersensitivity to alfuzosin or other ingredients.
  • Patients taking potent CYP3A4 inhibitors (such as certain antifungal or antiretroviral drugs).
  • Patients on concomitant administration with other alpha-1 receptor blockers.

Age and Organ Function Restrictions

Category Official Regulatory Status
Age Restriction (Pediatric) Not indicated for the pediatric population (children and adolescents) as efficacy has not been demonstrated.
Age Restriction (Gender) The therapeutic indication does not apply to women, including during pregnancy or lactation.
Severe Renal Impairment Not recommended or should be used with caution in patients with severe kidney impairment (creatinine clearance < 30 mL/min) due to limited safety data.
Cardiovascular Caution Caution is advised for patients with a history of QT prolongation or pre-existing coronary artery disease.

Connection to the overall eligibility profile:

Official regulatory documents establish clear, absolute contraindications that prohibit use in patients with specific organ function issues (moderate/severe liver impairment), certain cardiovascular histories, and concurrent use of specific drug classes. For all other populations, including adults with normal to mild/moderate organ impairment, use is permitted under the labeled conditions, while use in the pediatric population is explicitly not indicated.

Advertisements

What should I know about interactions with other medicines?

Xatral XL (alfuzosin) can interact with several other medications, which may increase the risk of side effects, particularly hypotension (low blood pressure) and fainting. It is essential to inform your doctor or pharmacist about all prescription, over-the-counter, and herbal supplements you are currently taking.

Contraindicated Combinations

Certain combinations must be avoided due to significant risk of serious adverse effects:

  • Other Alpha-1 Blockers: Such as tamsulosin, prazosin, or doxazosin. Combining these with Xatral XL is contraindicated, as it can cause a severe drop in blood pressure.
  • Potent CYP3A4 Inhibitors: Medications that strongly inhibit the CYP3A4 enzyme, such as certain antifungals (e.g., ketoconazole, itraconazole) and protease inhibitors (e.g., ritonavir). These increase the concentration of Xatral XL in the blood, leading to an increased risk of side effects, including QT interval prolongation.

Combinations Requiring Caution

Consult your healthcare provider if you are taking any of the following, as blood pressure monitoring may be necessary:

  • Antihypertensive Medications: Including beta-blockers, calcium channel blockers, and ACE inhibitors. Concomitant use increases the risk of hypotension and dizziness.
  • Nitrates: Medicines used for heart pain (angina), such as nitroglycerin, as the risk of hypotension is increased.
  • Phosphodiesterase Type 5 (PDE5) Inhibitors: Medications for erectile dysfunction (e.g., sildenafil, tadalafil) may significantly increase the risk of low blood pressure, particularly when used within hours of taking Xatral XL.
  • Grapefruit Juice: Consumption of grapefruit juice may increase alfuzosin blood levels, potentially increasing side effects. Avoid drinking large quantities.
Advertisements

Mechanism of Action

How Xatral XL Works: Mechanism of Action

Alfuzosin hydrochloride (Xatral XL) works by engaging mechanisms that regulate smooth muscle contraction, focusing on specific receptors in the lower urinary system.


Targeted alpha1-Adrenoceptor Blockade

This domain covers the drug's molecular interaction with its primary biological targets: the Alpha-1 Adrenoceptors (alpha1-ARs) concentrated in the prostate and bladder neck. Alfuzosin acts as a competitive antagonist, physically blocking these receptors and preventing the binding of the body's natural contracting agent, Norepinephrine. This interaction initiates the critical first step by dampening the signal that drives muscular tone.


Regulation of Smooth Muscle Contraction Cascades

This domain explains the downstream consequence of receptor blockade at the cellular level. By preventing alpha1-AR activation, the drug modifies the early molecular steps that normally lead to an increase in intracellular calcium ions ( Ca^2+) within the smooth muscle cells. This reduction in the calcium signal suppresses the cellular contractile machinery, leading directly to the relaxation of the smooth muscle tissue and resulting in a decrease in muscular tension within the lower urinary pathway.

Advertisements

Dosage and Administration Information

Instruction Map: How to Use Xatral XL — Administration Guidelines

This map summarizes the administration instructions for Xatral XL (alfuzosin 10 mg prolonged-release tablet).


Administration Scope Instruction
Route of administration Oral use (swallowed).
Dosing schedule One 10 mg tablet per day.
Timing in relation to meals Must be taken immediately after a meal, typically the evening meal. Consistent intake with food is required due to reduced absorption in a fasting state.
Preparation requirements None other than swallowing with a glass of water.
Age-group administration rules Older Adults (≥ 65 years): Referenced for use in the Acute Urinary Retention (AUR) context. Pediatric: Not indicated for use in children aged 2 to 16 years.
Missed-dose rules If a dose is missed, the patient should not take a double dose. The patient should simply take the next dose at the usual time.
Special procedural conditions The tablet must be swallowed whole. It must not be crushed, chewed, or split as this would compromise the prolonged-release properties.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral
Frequency pattern Daily (once a day)
Basis of use Standard prescribing specifications
Use-context constraints Long-term (for BPH symptoms) or Short-term (3-4 days for AUR)

Procedural Structure

Step sequence:

  • Take one 10 mg prolonged-release tablet per day.
  • Take the tablet immediately after a meal (e.g., the evening meal).
  • The tablet must be swallowed whole with fluid.
  • Do not crush, chew, split, or grind the tablet.
  • If a dose is missed, do not take an extra tablet; continue the regimen with the next scheduled dose.

Connection to the overall use protocol: The usage protocol requires the oral administration of a 10 mg prolonged-release tablet once daily, taken consistently with food. This regimen is critical to ensure the drug's intended absorption rate and its steady, sustained delivery over the 24-hour dosing interval. The physical handling instructions—specifying that the tablet cannot be broken—are necessary to preserve the integrity and proper function of the prolonged-release mechanism.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence Overview

Research evidence has explored whether Xatral XL (alfuzosin extended-release) was linked to changes in measures of Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). Studies investigating the compound have been conducted primarily in adult male populations.


Phase III Trial Findings

Phase III clinical trials were designed to assess participant responses to the drug over periods of up to 12 months. These trials examined whether the drug, as a sole agent, was associated with changes in measured disease markers.

  • Symptom Scoring: Early findings from multicenter trials examined whether the drug was linked to differences in primary symptom severity scores, such as those measured by the International Prostate Symptom Score (IPSS).
  • Combination Use: Studies have investigated the use of alfuzosin in combination with a urethral catheter for Acute Urinary Retention (AUR) related to BPH, primarily following catheter removal.
  • Objective Measures: Research assessed whether the drug was associated with changes in objective urinary flow parameters, including maximum urinary flow rate (Qmax) and post-void residual (PVR) urine volume.

Pharmacokinetics and Research Gaps

Pharmacokinetic studies investigated whether co-administration with food influences the drug's absorption, noting that absorption is increased when taken after a meal. Research also assessed the drug's metabolism and excretion profile.

Gaps in Evidence: Currently, evidence is limited regarding the drug's long-term effects beyond two years in the study population. Furthermore, specific studies have not yet established outcomes for people with severe kidney or liver impairment, which may affect drug clearance. Further research is ongoing to assess whether the drug yields varying results relative to control or comparison groups.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Xatral XL (FAQ)

Q: Is Xatral XL used to treat both BPH symptoms and high blood pressure?

Xatral XL is officially indicated for the treatment of functional symptoms of Benign Prostatic Hyperplasia (BPH), which is associated with an enlarged prostate. While the medicine belongs to a drug class known for its ability to reduce blood pressure, official information states it is not approved or indicated as a treatment for high blood pressure.


Q: Does Xatral XL affect the size of the prostate gland itself?

The drug's mechanism involves relaxing the smooth muscles in the prostate and bladder neck, which helps to improve the flow of urine. Regulatory information and the mechanism of action do not describe any way in which the drug would reduce the actual physical size of the prostate gland.


Q: Is the dizziness from Xatral XL more likely to occur when first starting the treatment?

According to official product information, side effects related to blood pressure changes, such as postural hypotension (dizziness or lightheadedness upon standing), are noted to be most common at the start of treatment. These effects are generally described as transient.


Q: Are there reports of irregular heartbeat or palpitations related to Xatral XL use?

Official regulatory safety reports document both palpitations (feeling a pounding or skipping heartbeat) and tachycardia (an abnormally fast heart rate) as uncommon side effects associated with Xatral XL.


Q: What are the warnings regarding Xatral XL use in people with kidney impairment?

Official regulatory documents indicate that Xatral XL is generally not recommended or should be used with caution in patients who have severe kidney impairment (when kidney function is significantly reduced). This is due to limited safety data in this specific population.


Q: What specific information should be shared with an eye surgeon if a patient is taking or has taken Xatral XL?

Official documents suggest patients should inform their eye surgeon about their current or previous use of Xatral XL, even if treatment has stopped. This is important because the drug is associated with a condition called Intraoperative Floppy Iris Syndrome (IFIS), which may require the surgeon to use modified techniques during cataract or glaucoma surgery.


Q: Is Xatral XL considered a treatment for an enlarged prostate in the long term?

Xatral XL is indicated for the management of the functional symptoms of BPH and is used for long-term treatment of this condition. Clinical studies have examined its use over periods of up to 12 months for symptom relief in BPH.


Q: How quickly does Xatral XL typically start to relieve urinary symptoms?

Official regulatory documents indicate that improvement in objective urinary flow rate (Qmax) has been observed starting from the first dose of Xatral XL.


Q: How long does the effect of one Xatral XL tablet last in the body?

The XL (eXtended-Length) formulation is specifically designed to provide a sustained, consistent release of the drug. Official pharmacokinetic data indicates that the sustained release formulation supports its effect for up to 24 hours.


Q: Can Xatral XL potentially increase the effects of alcohol consumption?

Yes, official safety information suggests that consuming alcohol while using Xatral XL may potentially increase the risk of developing low blood pressure. This increase in risk can lead to symptoms like lightheadedness, dizziness, or fainting.


Q: What is the potential interaction between Xatral XL and PDE5 inhibitors (like sildenafil or tadalafil)?

Regulatory information notes that caution is advised when Xatral XL is used with PDE5 inhibitors (used for erectile dysfunction) because both classes of drugs can cause blood vessels to relax (vasodilation). Using them together significantly increases the potential risk of developing low blood pressure (hypotension) and related symptoms.


Q: Is there a specific warning about consuming grapefruit or grapefruit juice while taking Xatral XL?

Official information about the drug's metabolism describes it as being processed by the CYP3A4 enzyme in the body. Since grapefruit juice is known to inhibit this enzyme, consuming it may increase the drug concentration in the body, potentially raising the risk of side effects.


Q: What information is provided about the relationship between Xatral XL and sexual function?

Official regulatory documents state that the drug's action on BPH symptoms does not have a detrimental effect on sexual function.


Q: What should be known about the risk of a prolonged, painful erection (priapism) with Xatral XL?

Priapism (a persistent, painful erection unrelated to sexual activity) is a rare but serious side effect reported with alpha-1 blockers. This condition is a medical emergency that requires immediate medical attention if it occurs.


Q: Can Xatral XL cause new or worsened chest pain (angina) in some individuals?

In patients who already have pre-existing coronary artery disease, official warnings indicate there is a very rare risk that Xatral XL may cause new or worsened chest pain (angina pectoris). If symptoms of angina should appear or worsen, regulatory documents advise the discontinuation of the drug.


Q: Does Xatral XL carry a warning about potential effects on the heart's electrical activity (QT prolongation)?

Yes. Official warnings advise caution for patients who have acquired or congenital QT prolongation or who are taking medications that prolong the QT interval, due to the risk of this rare, dangerous heart rhythm problem.


Q: Does Xatral XL interact with over-the-counter supplements or herbal products?

Regulatory guidance recommends informing the healthcare provider about all prescription and over-the-counter (OTC) medicines, vitamins, minerals, herbal products, and supplements being used. This guidance helps manage potential drug-drug interactions.


Q: Can Xatral XL cause or contribute to headaches?

Headache is clearly documented in official regulatory safety data as a common side effect associated with the use of Xatral XL.


Q: Do side effects like a runny or stuffy nose commonly occur with Xatral XL?

Official safety information classifies rhinitis (symptoms like a runny or stuffy nose) as an uncommon side effect of Xatral XL.


Q: Are there reports of gastrointestinal issues, such as diarrhea or stomach upset, associated with this medication?

Yes. Abdominal pain and nausea are listed as common side effects, while diarrhea is documented as an uncommon side effect in regulatory safety reports.


Q: Is Xatral XL prescribed to patients who have had a history of fainting (syncope) episodes?

Regulatory caution notes that special care is required for patients with conditions that predispose them to symptomatic orthostatic hypotension (low blood pressure upon standing), or a history of certain types of fainting (micturition syncope).


Q: What is the general guidance regarding driving or operating machinery when first starting Xatral XL?

Due to the documented risks of dizziness, drowsiness, fainting, and visual disturbances, particular caution is required when driving or operating machinery, especially when starting treatment. It is noted that patients should be aware of these effects before engaging in such activities.


Q: Does Xatral XL affect the body's temperature regulation, such as causing flushing or sweating?

Yes. Regulatory safety data lists flushing as an uncommon side effect, and generalized sweating has been reported in post-marketing surveillance for Xatral XL.


Q: Are there specific instructions about when to take Xatral XL relative to the time of day?

The drug is intended to be taken once daily and consistently with a meal, such as the evening meal, to ensure proper absorption. This information is detailed in the official administration instructions.

Advertisements

How should Xatral XL be stored and disposed of?

How to Store and Dispose of Xatral XL

Official Storage Requirements

Xatral XL (alfuzosin prolonged-release tablets) must be stored under specific conditions to maintain efficacy. Keep the medicine out of the sight and reach of children and pets. Store the tablets at room temperature, typically not above 25°C or 30°C, depending on the specific product label. It is mandatory to protect the medicine from moisture, excessive heat, and direct sunlight; therefore, do not store it in a bathroom or near a sink. Always keep the tablets in the original container or blister pack until the time of use to maintain the integrity of the prolonged-release formulation.

Disposal Instructions

Do not use the medicine after the expiration date printed on the packaging. To protect the environment, official regulations require that unused or expired Xatral XL not be disposed of in household waste or wastewater (such as flushing down a toilet or sink). Instead, return the product to a pharmacist or local community drug disposal program for safe and proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Xatral XL found in:

A-Z Index: